Bionano Genomics Inc
$ 1.31
1.55%
20 Apr - close price
- Market Cap 14,308,700 USD
- Current Price $ 1.31
- High / Low $ 1.33 / 1.27
- Stock P/E N/A
- Book Value 4.14
- EPS -4.85
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.66 %
- 52 Week High 5.50
- 52 Week Low 1.06
About
Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.
Analyst Target Price
$5.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-24 | 2025-11-13 | 2025-08-14 | 2025-06-18 | 2025-03-03 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-03-05 | 2023-11-08 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.03 | -1.59 | -1.99 | -10.7888 | -7.73 | -0.2675 | -0.22 | -0.51 | -0.9593 | -1 | -1.24 | -0.12 |
| Estimated EPS | -4.14 | -0.5 | -0.54 | -3.0233 | -6 | -0.21 | -0.42 | -0.64 | -0.87 | -0.97 | -1.03 | -0.11 |
| Surprise | 4.11 | -1.09 | -1.45 | -7.7655 | -1.73 | -0.0575 | 0.2 | 0.13 | -0.0893 | -0.03 | -0.21 | -0.01 |
| Surprise Percentage | 99.2754% | -218% | -268.5185% | -256.8551% | -28.8333% | -27.381% | 47.619% | 20.3125% | -10.2644% | -3.0928% | -20.3883% | -9.0909% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.81 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BNGO
2026-04-18 03:08:54
This article analyzes Bionano Genomics Inc (BNGO) and recommends a "Hold" position for beginner investors due to a lack of positive momentum, weak financial performance, and no significant catalysts. While technical indicators show slight bullish momentum, the company's Q4 2025 financial results presented declines in revenue, net income, and EPS, despite a slight improvement in gross margin. Analysts have also lowered their price targets, citing increased share count, suggesting dilution concerns.
2026-04-13 18:39:12
H.C. Wainwright has reiterated its Buy rating for Bionano Genomics (BNGO.US) but has adjusted its target price from $7 to $6. Analyst Yi Chen, who has a 36.4% success rate and a -4.7% average return over the past year according to TipRanks, made the revision. The article emphasizes that this information is for informational purposes only and not an investment recommendation.
2026-04-13 14:39:12
The optical genome mapping (OGM) market is projected to grow significantly from $0.23 billion in 2025 to $0.74 billion by 2030, driven by the limitations of next-generation sequencing in detecting large structural variants, increased genomic research funding, and rising prevalence of genetic disorders. Key trends include OGM's adoption for structural variant detection in rare diseases and cancer, its use in clinical diagnostics, and the growing demand for precision medicine. Major players like Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies are leading innovation, with North America holding the largest market share and Asia-Pacific showing rapid growth potential.
2026-04-13 11:43:24
H.C. Wainwright has lowered its price target for Bionano Genomics (NASDAQ:BNGO) to $6 from $7, while maintaining a Buy rating. This adjustment is primarily due to an increased share count, despite the stock trading near its 52-week low and an InvestingPro analysis suggesting it may be undervalued. Bionano Genomics reported a revenue decline for Q4 2025 and the full year 2025, but management provided 2026 revenue guidance indicating potential topline growth of up to 16%.
2026-04-13 10:27:00
The optical genome mapping (OGM) market is experiencing rapid growth, projected to expand from $0.23 billion in 2025 to $0.74 billion by 2030, driven by the limitations of next-generation sequencing, increased genomic research funding, and rising demand for advanced cytogenetic techniques. Key players like Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies are innovating with OGM-based laboratory-developed tests and strategic collaborations to enhance structural variant detection. Precision medicine is a significant growth driver, as OGM provides crucial insights into genetic changes for personalized treatments.
2026-04-04 09:38:00
J.P. Morgan maintained a Hold rating on Johnson & Johnson (JNJ) with a price target of $250.00, while BioNano Genomics (BNGO) received a Buy rating from Maxim Group with a price target of $4.00. Johnson & Johnson has a Moderate Buy consensus with a 3.6% upside, and BioNano Genomics also has a Moderate Buy consensus with a price target of $5.50. This indicates varied analyst opinions on these healthcare stocks.
